Each company’s board of directors approved the acquisition.
The FDA approved Tavneos, the brand name for the generic avacopan, in October 2021, to be an additional treatment for adult patients with a severe, rare condition in which the immune system attacks blood vessels. In a clinical trial, Tavneos had a 65.7 remission rate among study participants.
The oral drug is “a transformative, first-in-class treatment for ANCA-associated vasculitis,” Robert Bradway, Amgen’s CEO and chairman, stated in the news release.
Mr. Bradway said he was excited about the Taveneos launch and helping more patients with the sometimes life-threatening immune system disease.
Active-neutrophil cytoplasmic autoantibody-associated vasculitis affects about 200 million people, according to the FDA.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
